摘要
目的:探讨中医药联合化疗对非小细胞肺癌术后患者血清TK1(胸苷激酶1)浓度及患者生存预后的影响。方法:将100例非小细胞肺癌术后患者作为研究对象,根据所采取的治疗手段将研究对象按随机方法分成对照组和治疗组各50例。对照组单纯进行化疗,而治疗组在对照组的基础上联合中医药治疗。比较术后两组患者开始治疗前不同血清TK1浓度值行Kaplan-Meier生存分析,卡方检验对相关临床病理特征关系进行分析,对独立预后因素行单因素分析、Cox回归分析。t检验比较两组治疗后血清TK1浓度差异。结果:100例非小细胞肺癌术后患者TK1(≤0.5 pmol/L)生存期明显高于TK1(>0.5 pmol/L)的生存期(P<0.01);在相关临床病理特征方面,T分期(P=0.010)、N分期(P=0.002)与血清TK1浓度相关;在预后方面,T分期(HR=1.739;P=0.006)和N分期(HR=1.694;P<0.001)是非小细胞肺癌患者的独立预后因素。结论:中医药联合化疗有效地抑制了非小细胞肺癌患者血清TK1的表达,从而发挥了抑制肿瘤增长的作用,有利于患者生存期的延长,改善患者生活质量,同时血清TK1可作为治疗非小细胞肺癌患者疗效评价的重要预后因素。
Objective： To study the effect of the influence of the concentration of serum TK1 and survival prognosis of traditional Chinese medicine combined with chemotherapy in non-small cell lung cancer after surgery. Methods： According to the treatment method, 100 patients with non-small cell lung cancer after surgery as the research object are divided into a control group and a treatment group according to the random method（n=50）. The control group were treated with chemotherapy, and the treatment group were treated with traditional Chinese medicine on the basis of the control group. The different level of serum TK1 in all patients before treatment were compared with Kaplan-Meier survival analysis, the clinical and pathological characters were compared by chi square test and the independent prognostic factors for univariate analysis and Cox regression analysis. The different level of serum TK1 in two groups after treatment were compared by T test. Results： All Patients＇ postoperative survival in TK1（≤0.5 pmol/L） was significantly higher in TK1（0.5 pmol/L）,（P〈0.01）; in the clinical and pathological features, T stage（P=0.010）, N staging（P=0.002） showed relationship with TK1; in terms of prognosis, T staging（HR=1.739, P=0.006） and N staging（HR=1.694, P〈0.001） are independent prognostic factors of patients with non-small cell lung cancer. Conclusion： Traditional Chinese medicine combined with chemotherapy effectively inhibited the expression of the serum concentration of TK1 in the patients with nonsmall cell lung cancer after surgery, so as to play a role in inhibiting tumor growth, which is conducive to prolonged survival of patients, also serum TK1 can be used as an important prognosis factor of curative effect evaluation in non-small cell lung cancer patients.
出处
《临床与病理杂志》
2017年第11期2383-2388,共6页
Journal of Clinical and Pathological Research
关键词
中医药
化疗
非小细胞肺癌
胸苷肌酶1
预后因素
traditional Chinese medicine
chemotherapy
non-small cell lung cancer
thymidine kinase 1
prognosis
